Evidence strength for the context described on this page.
PEPTIDE ATLAS / ENERGY & LONGEVITY / HUMANIN
InvestigationalPreclinical
Humanin
ALSO KNOWN ASMitochondrial-derived peptide
A mitochondrial stress-response peptide studied mainly as biology, not as an established human therapy.
01CATEGORYEnergy & longevity
02REGULATORY STATUSInvestigational
03COMMON ROUTEMarketed for subcutaneous injection; no approved route
04DOSE BASISReported clinic/community use only
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Humanin is.
An endogenous mitochondrial-derived peptide investigated in aging, metabolism, neuroprotection and cellular stress. Commercial research products are not approved medicines.
HOW IT IS THOUGHT TO WORK
Reported in models to influence apoptosis, insulin signaling, inflammation and stress resistance through intracellular and receptor-mediated pathways.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Promising preclinical signals across several disease models
- No established clinical wellness benefit
- Neuroprotection in healthy people
- Improved energy
- Diabetes prevention
- Human lifespan extension
Evidence grade: Preclinical. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Reported clinic/community use onlyMost commonly reported clinic range: 250 mcg–1 mg subcutaneously daily; some clinics use 2–5 mg two or three times weekly. These unapproved protocols may refer to native humanin or the much more potent S14G-humanin analog, so the exact molecule must be confirmed. No therapeutic human dosing trial has validated either range.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Commonly reported for 8–12 weeks followed by a 4–8 week break; there is no human evidence for this cycling scheme.
- How to interpret it
- Confirm whether the product is native humanin or an analog such as HNG/S14G-humanin; potency may differ substantially. No therapeutic human dosing trial validates these clinic numbers.
- Route
- Marketed for subcutaneous injection; no approved route
- Duration
- Reported cycles: 8–12 weeks with a break; no established course
- Men & women
- No validated human or sex-specific regimen. Reported ranges are generally the same for men and women.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- No clinical monitoring standard exists
SAFETY
Risks, red flags and reasons to avoid it.
- Unknown human toxicity and pharmacokinetics
- Unknown effects on cell survival pathways
- Product purity and identity risk
- Human use of research material
- Cancer without specialist research oversight
- Claims that endogenous means safe
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Laboratory research market; not an approved human drug.
Humanin is valuable research biology. Selling a vial does not convert that biology into a tested therapy.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP